Article
Oncology
Harrison Naung, Kenneth J. Cohen
Summary: Therapy for medulloblastoma in patients < 4 years old may omit radiotherapy due to anticipated neurocognitive deficits. Chemotherapy regimen without radiation can yield high progression-free survival rates. Modified approaches, such as reducing intrathecal methotrexate doses and using lumbar administration, show promising results in young children with favorable outcomes.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Valentina Conti, Manuela Cominelli, Valentina Pieri, Alberto L. Gallotti, Ilaria Pagano, Matteo Zanella, Stefania Mazzoleni, Flavia Pivetta, Monica Patane, Giulia M. Scotti, Ignazio S. Piras, Bianca Pollo, Andrea Falini, Alessio Zippo, Antonella Castellano, Roberta Maestro, Pietro L. Poliani, Rossella Galli
Summary: mTORC1 hyperactivation is associated with unfavorable histological features in p53-mutant SHH MB patients, and inhibiting mTORC1 can reduce tumor burden and aggressiveness, potentially serving as a specific druggable target for this subset of MB.
Article
Medical Laboratory Technology
Haoyu Ruan, Zhe Wang, Kun Chen, Xuemei Tang, Tianling Ding, Chao Zhang, Ming Guan
Summary: This study reported a rare case of primary leptomeningeal anaplastic large cell lymphoma (PL-ALCL) and performed single-cell RNA sequencing to analyze the transcriptome characteristics of the cerebrospinal fluid anaplastic large cells (CSF-ALCs). The analysis revealed specific gene upregulation and altered transcription factor activity in CSF-ALCs, providing insight for the diagnosis and mechanism research of PL-ALCL.
CLINICA CHIMICA ACTA
(2022)
Article
Oncology
V. Subbiahy, S. Kuraviy, S. Ganguly, D. R. Welch, C. J. Vivian, M. U. Mushtaq, A. Hegde, S. Iyer, A. Behrang, S. M. Ali, R. W. Madison, J. M. Venstrom, R. A. Jensen, J. P. McGuirk, H. M. Amin, R. Balusu
Summary: The study demonstrates that Ceritinib shows inhibitory effects on the fusion kinase NPM1-ALK and induces apoptosis of lymphoma cells in vitro and in vivo. Treatment with Ceritinib in the NPM1-ALKthorn ALCL xenograft model resulted in tumor regression and improved survival. Among 19,272 patients sequenced, 0.30% harbored ALK fusions, including various hematologic malignancies.
Review
Immunology
Jennifer E. Agrusa, Emily R. Egress, Eric J. Lowe
Summary: ALCL is the most common mature T-cell non-Hodgkin lymphoma in children/adolescents, and improved therapies are needed. Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, has shown safety and efficacy in clinical trials for ALCL in both pediatric and adult populations. Future studies should investigate combination therapies with brentuximab vedotin and other targeted agents.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Hematology
Fateeha Furqan, Kwang W. Ahn, Yue Chen, Manmeet Kaur, Syed A. Abutalib, Nausheen Ahmed, Sairah Ahmed, Mohamed A. Kharfan-Dabaja, Johnathan Friedberg, Tara Gregory, LaQuisa Hill, Cole Sterling, Stephan K. Barta, Mazyar Shadman, Miguel-Angel Perales, Jasmine Zain, Alex F. Herrera, Craig Sauter, Mehdi Hamadani
Summary: This study evaluated the outcomes of allo-HCT in patients with relapsed/refractory ALCL and found that it can result in durable disease control in a significant proportion of patients. However, refractory disease and racial minority status predicted inferior outcomes after allo-HCT.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Review
Oncology
Xin-Rui Zhang, Pham-Ngoc Chien, Sun-Young Nam, Chan-Yeong Heo
Summary: Anaplastic large cell lymphoma is a rare disease with four subtypes that differ in clinical symptoms, gene changes, prognosis, and treatment.
Review
Oncology
Rui Wu, Megan S. Lim
Summary: Anaplastic large cell lymphomas (ALCL) are mature T-cell neoplasms characterized by the expression of CD30 and anaplastic cytomorphology. ALCL can be classified into ALK+ ALCL, ALK- ALCL, and breast implant-associated ALCL (BI-ALCL). ALK-ALCLs are a heterogeneous group with different clinical, immunophenotypic, and genetic features. There are various genetic abnormalities and fusion partner genes identified in ALCL, and some remain to be characterized. This review also discusses the pathobiological features of primary cutaneous ALCL and recent insights into ALCL pathogenesis.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Yichen Wang, Qi Zhang, Yufang Tan, Wenchang Lv, Chongru Zhao, Mingchen Xiong, Kai Hou, Min Wu, Yuping Ren, Ning Zeng, Yiping Wu
Summary: This article provides a review on the etiology, pathogenesis, diagnosis, and therapy of breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL). It also reviews the physical characteristics of breast implants and their potential pathogenic effect, aiming to provide a foundation for the optimal choice of implants with minimal morbidity.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Shih-Lung Chen, Kai-Chieh Chan
Summary: ALCL is a rare form of non-Hodgkin's lymphoma, especially when it occurs in the external auditory canal (EAC). Diagnosis of ALCL in the EAC region can be challenging, but a combination of imaging, histopathological examination and IHC staining can confirm the presence of the disease. Treatment options include radiotherapy, chemoradiotherapy, and targeted therapies like Brentuximab vedotin for ALK-positive ALCL.
Article
Oncology
Kazunori Kawasoe, Tatsuro Watanabe, Nao Yoshida-Sakai, Yuta Yamamoto, Yuki Kurahashi, Keisuke Kidoguchi, Hiroshi Ureshino, Kazuharu Kamachi, Yuki Fukuda-Kurahashi, Shinya Kimura
Summary: This article investigates the efficacy of combination therapy with alectinib and DNA-demethylating agents for the treatment of ALK+ ALCL. The study found that this combination therapy can synergistically suppress ALCL cell proliferation and induce gene expression reprogramming. This therapy has the potential to improve treatment outcomes in patients with ALK+ ALCL.
Article
Oncology
Camille Daugrois, Chloe Bessiere, Sebastien Dejean, Veronique Anton-Leberre, Therese Commes, Stephane Pyronnet, Pierre Brousset, Estelle Espinos, Laurence Brugiere, Fabienne Meggetto, Laurence Lamant
Summary: The study identified genes associated with clinical outcomes in ALK-positive anaplastic large cell lymphoma by analyzing gene expression profiling of 48 samples, particularly highlighting the potential role of the FN1 gene. Furthermore, FN1, along with other genes, was found to predict both prognosis and therapeutic response in anaplastic lymphomas.
Article
Medicine, General & Internal
Hai-Xi Mu, Xiao-Qiong Tang
Summary: This case had rare transition from PC-ALCL to sALCL, with high expression of Ki-67 initially. Auto-ASCT combined with demethylation drugs effectively maintained CR and prolonged progression-free survival.
WORLD JOURNAL OF CLINICAL CASES
(2023)
Review
Oncology
Martina Vittorietti, Sergio Mazzola, Claudio Costantino, Daniele Domenico De Bella, Santo Fruscione, Nicole Bonaccorso, Martina Sciortino, Davide Costanza, Miriam Belluzzo, Alessandra Savatteri, Fabio Tramuto, Paolo Contiero, Giovanna Tagliabue, Palmira Immordino, Francesco Vitale, Arianna Di Napoli, Walter Mazzucco
Summary: This study investigated the main characteristics of breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) and the factors predicting BIA-ALCL onset in patients with and without an implant replacement. The findings suggest that implant substitution and/or capsulectomy may delay the onset of the disease, but there is a risk of earlier reoccurrence in these patients. Additionally, the time to BIA-ALCL onset slightly increases with age.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Jean-Philippe Merlio, Marshall E. Kadin
Summary: ALCL is a tumor of activated T cells and possibly innate lymphoid cells with several subtypes according to clinical presentation and genetic lesions. The review focuses on the biology of the main ALCL subtypes and the potential for targeted therapies based on the identification of signaling pathways and ALCL-derived cytokines.